NCT04367090View on ClinicalTrials.gov

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

August 10, 2022

Study Completion Date

May 24, 2023

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Docetaxel, trastuzumab

Docetaxel and trastuzumab once per cycle

DRUG

Pyrotinib

Pyrotinib 400/320 mg orally daily

Trial Locations (1)

510000

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04367090 - Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter